Therefore, the systemic clinical symptoms influenced by anti-SSA/Ro antibodies may also contribute to the observation that SSA-positive pSS patients tend to be diagnosed at a significantly younger age than their ACA-positive counterparts. This evidence concerns the gene RO60 and peeling skin syndrome.